#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Dif­ferential Dia­gnosis of Tauopathies –  a Clinical Approach


Authors: R. Rusina 1,2;  R. Matěj 3,4;  E. Růžička 1;  J. Roth 1
Authors‘ workplace: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze 1;  Neurologické oddělení, Thomayerova nemocnice, Praha 2;  Oddělení patologie a molekulární medicíny, Thomayerova nemocnice, Praha 3;  Ústav patologie, 3. LF UK v Praze 4
Published in: Cesk Slov Neurol N 2015; 78/111(5): 526-534
Category: Review Article
doi: https://doi.org/10.14735/amcsnn2015526

Overview

Tauopathies are neurodegenerative disorders characterized by accumulation of abnormally modified forms of the tau-protein, predominantly in frontal, temporal and parietal cortical regions, basal ganglia and in the midbrain. Tauopathies are well defined from the molecular biological and biochemical point of view; clinical symptoms may be, however, heterogeneous. Common signs of frontotemporal lobar degenerations include a more or less prominent syndrome of frontotemporal dementia. On the other hand, the clinical picture of frontotemporal dementia may not be caused by a tauopathy only; in many cases the underlying etiopathogenic cause is different. The aim of our review is to classify the relationship between tauopathies and frontotemporal lobar degenerations. This review contains a proposal of a practical approach to refining clinical diagnosis of the different tauopathies.

Key words:
neurodegeneration – tauopathy – frontotemporal lobar degeneration –progressive supranuclear palsy – progressive aphasia – corticobasal syndrome

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manu­script met the ICMJE “uniform requirements” for biomedical papers.


Sources

1. Spil­lantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12(6): 609– 622. doi: 10.1016/ S1474‑ 4422(13)70090‑ 5.

2. Peden AH, Ironside JW. Molecular pathology in neurodegenerative diseases. Cur­r Drug Targets 2012; 13(12): 1548– 1559.

3. Wil­liams DR. Tauopathies: clas­sification and clinical update on neurodegenerative diseases as­sociated with microtubule‑as­sociated protein tau. Intern Med J 2006; 36(10): 652– 660.

4. Wil­liams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ et al. Pathological tau burden and distribution distinguishes progres­sive supranuclear palsy‑ parkinsonism from Richardson‘s syndrome. Brain 2007; 130(6): 1566– 1576.

5. Rademakers R, Neuman­n M, Mackenzie IR. Advances in understand­ing the molecular basis of frontotemporal dementia. Nat Rev Neurol 2012; 8(8): 423– 434. doi: 10.1038/ nrneurol.2012.117.

6. Rohan Z, Matej R. Cur­rent concepts in the clas­sification and dia­gnosis of frontotemporal lobar degenerations: a practical approach. Arch Pathol Lab Med 2014; 138(1): 132– 138. doi: 10.5858/ arpa.2012‑ 0510‑ RS.

7. Gros­sman M. The non‑fluent/ agram­matic variant of primary progres­sive aphasia. Lancet Neurol 2012; 11(6): 545– 555. doi: 10.1016/ S1474‑ 4422(12)70099‑ 6.

8. Dickson DW, Rademakers R, Hutton ML. Progres­sive supranuclear palsy: pathology and genetics. Brain Pathol 2007; 17(1): 74– 82.

9. Mathew R, Bak TH, Hodges JR. Dia­gnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry 2012; 83(4): 405– 410. doi: 10.1136/ jn­np‑ 2011‑ 300875.

10. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF,Abner EL, Alafuzof­f I et al. Primary age‑related tauopathy (PART): a com­mon pathology as­sociated with human aging. Acta Neuropathol 2014; 128(6): 755– 766. doi: 10.1007/ s00401‑ 014‑ 1349‑ 0.

11. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwel­l JL, Duf­fy JR et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66(1): 41– 48.

12. Litvan I, MacIntyre A, Goetz CG, Wen­n­ing GK, Jel­linger K, Verny M et al. Accuracy of the clinical dia­gnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55(7): 969– 978.

13. Onyike CU, Diehl‑ Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013; 25(2): 130– 137. doi: 10.3109/ 09540261.2013.776523.

14. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al. Sensitivity of revised diag­nostic criteria for the behavioral variant of frontotemporal dementia. Brain 2011; 134(9): 2456– 2477. doi: 10.1093/ brain/ awr179.

15. Gorno‑ Tempini ML, Hil­lis AE, Weintraub S, Kertesz A,Mendez M, Cappa SF et al. Clas­sification of primary progres­sive aphasia and its variants. Neurology 2011; 76(11): 1006– 1014. doi: 10.1212/ WNL.0b013e31821103e6.

16. Josephs KA, Duf­fy JR, Strand EA, Machulda M­M, Senjem ML, Master AV et al. Characteriz­ing a neurodegenerative syndrome: primary progres­sive apraxia of speech. Brain 2012; 135(5): 1522– 1536. doi: 10.1093/ brain// aws032.

17. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S336– S340. doi: 10.1016/ S1353‑ 8020(08)70027‑ 0.

18. Has­san A, Whitwel­l JL, Josephs KA. The corticobasal syndrome – Alzheimer‘s disease conundrum Expert Rev Neurother 2011; 11(11): 1569– 1578. doi: 10.1586/ ern.11.153.

19. Johanidesová S, Rusina R, Houška P, Kel­ler J, Matěj R.Alzheimerova nemoc probíhající pod obrazem kortikobazální degenerace –  kazuistika. Cesk Slov Neurol N 2012; 75/ 108(3): 373– 377.

20. L­ing H, O’Sul­livan SS, Holton JL, Revesz T, Mas­sey LA, Wil­liams DR et al. Does corticobasal degeneration exist? A clinicopathological re‑evaluation. Brain 2010; 133(7): 2045– 2057. doi: 10.1093/ brain/ awq123.

21. Steele JC, Richardson JC, Olszewski J. Progres­sive supranuclear palsy. A heterogeneous degeneration involv­ing the brain stem, basal ganglia and cerebel­lum with vertical supranuclear gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333– 359.

22. Liscic RM, Srulijes K, Gröger A, Maetzler W, Berg D. Dif­ferentiation of progres­sive supranuclear palsy: clinical, imag­ing and laboratory tools. Acta Neurol Scand 2013; 127(5): 362– 370. doi: 10.1111/ ane.12067.

23. Menšíková K, Kaňovský P, Kaiserová M, Nestrašil I, Bareš M. Proměnlivá tvář parkinsonské neurodegenerace. Cesk Slov Neurol N 2013; 76/ 109(1): 26– 34.

24. Respondek G, Roeber S, Kretzschmar H, Troakes C, Al‑ Sar­raj S, Gelpi E et al. Accuracy of the National Institute for Neurological Disorders and Stroke/ Society for Progres­sive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the dia­gnosis of progres­sive supranuclear palsy. Mov Disord 2013; 28(4): 504– 509. doi: 10.1002/ mds.25327.

25. Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of „heterogenous system degeneration“. Trans Am Neurol As­soc 1963; 88: 25– 29.

26. Wil­liams DR, de Silva R, Paviour DC, Pittman A, Watt HC,Kilford L et al. Characteristics of two distinct clinical phenotypes in pathological­ly proven progres­sive supranuclear palsy: Richardson‘s syndrome and PSP‑ parkinsonism. Brain 2005; 128(6): 1247– 1258.

27. Imai H, Nakamura T, Kondo T, Narabayashi H. Dopa‑ unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP? Adv Neurol 1993; 60: 622– 625.

28. Wil­liams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progres­sive supranuclear palsy. Mov Disord 2007; 22(15): 2235– 2241.

29. Josephs KA, Boeve BF, Duf­fy JR, Smith GE, Knopman DS,Parisi JE et al. Atypical progres­sive supranuclear palsy underly­ing progres­sive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11(4): 283– 296.

30. Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Grif­fin WS et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concur­rent Alzheimer‘s disease‑related pathology. Neuropathol Appl Neurobio­l 2005; 31(3): 270– 279.

31. Matěj R, Koukolík F. Nemoc s argyrofilními zrny: kazuistické sdělení prvních dvou případů dia­gnostikovaných v ČR a přehled literatury. Cesk Patol 2006; 42(2): 66– 70.

32. Rosen HJ, Gorno‑ Tempini ML, Goldman W, Per­ry RJ, Schuf­f N, Weiner M et al. Pattern of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58(2): 198– 208.

33. Rusz J, Bon­net C, Klempíř J, Tykalová T, Baborová E,Novotný M et al. Speech disorders reflect dif­fer­ing pathophysiology in Parkinson’s disease, progres­sive supranuclear palsy and multiple system atrophy. J Neurol 2015; 262(4): 992– 1001. doi: 10.1007/ s00415‑ 015‑ 7671‑ 1.

34. Dugger BN, Adler CH, Shil­l HA, Cavines­s J, Jacobson S, Driver‑ Dunckley E et al. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014; 20(5): 525– 529. doi: 10.1016/ j.parkreldis.2014.02.012.

35. Rusina R, Pazdera L, Kulišťák P, Vyšata O, Matěj R. Pick and Alzheimer diseases: a rare comorbidity present­ing as corticobasal syndrome. Cogn Behav Neurol 2013; 26(4): 189– 194. doi: 10.1097/ WN­n.0000000000000011.

36. Menšíková K, Matěj R, Tučková L, Rusina R, Ehrman­n J, Kaňovský P. Progres­sive supranuclear palsy phenotype mimick­ing synucleinopathies. J Neurol Sci 2013; 329(1– 2): 34– 37. doi: 10.1016/ j.jns.2013.03.008.

37. Litvan I, Agid Y, Calne D, Campbel­l G, Dubois B, Duvoisin RC et al. Clinical research criteria for the dia­g­nosis of progres­sive supranuclear palsy (Steele‑ Richardson‑ Olszewski syndrome): report of the NINDS‑ SPSP international workshop. Neurology 1996; 47(1): 1– 9.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 5

2015 Issue 5

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#